Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD (Sequencing)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Oregon Research Institute
ClinicalTrials.gov Identifier:
NCT00680966
First received: May 16, 2008
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to determine whether it is more effective to treat adolescents, with diagnoses of both depression and substance use disorder, with a treatment addressing the substance use first and then treating the depression or to first treat the depression and then treat the substance use or whether treating both disorders simultaneously is most effective.

It is expected that treatment of both disorders at the same time will be the most effective.


Condition Intervention
Adolescent
Depression
Substance Use Disorders
Behavioral: Adolescent Coping With Depression/Functional Family Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD

Further study details as provided by Oregon Research Institute:

Primary Outcome Measures:
  • Children's Depression Rating Scale [ Time Frame: Intake, Mid-Treatment, Post, 6 months and 12 months follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time Life Follow Back [ Time Frame: Intake, Mid-Treatment, Post, 6 months and 12 months follow-up ] [ Designated as safety issue: No ]

Enrollment: 180
Study Start Date: January 2008
Study Completion Date: June 2013
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TX1
Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
Behavioral: Adolescent Coping With Depression/Functional Family Therapy
ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
Other Names:
  • FFT
  • ACWD
Experimental: TX 2
ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
Behavioral: Adolescent Coping With Depression/Functional Family Therapy
ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
Other Names:
  • FFT
  • ACWD
Experimental: TX 3
Combination of an augmented FFT and ACWD - Integrated treatment
Behavioral: Adolescent Coping With Depression/Functional Family Therapy
ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
Other Names:
  • FFT
  • ACWD

Detailed Description:

Comorbidity is a well established aspect of adolescent psychopathology. The majority of adolescents entering treatment have more than one condition. This study will evaluate service delivery methods of integrating empirically supported interventions for depression and non-nicotine substance use disorders (SUD)in an effort to improve treatment engagement, response, and maintenance of gains. The two examined interventions are the Adolescent Coping With Depression course (ACWD) and Functional Family Therapy (FFT).

This study will expand upon previous research by systematically treating both depression and SUD. Over a 5 year period, 180 adolescents with depression/SUD and their parents/guardians will be recruited in Oregon and New Mexico and randomly assigned to 1 of 3 conditions: (a) FFT followed by ACWD, (b) ACWD followed by FFT, or (c) an intervention combining and augmenting FFT and ACWD (Integrated Treatment). Each treatment arm will consist of 24 sessions provided over 20 weeks. Participants will be assessed at intake, after the provision of 6, 12 (Mid-treatment), 18 and 24 (Post-treatment)treatment sessions, and at 6 and 12 month follow-ups.

  Eligibility

Ages Eligible for Study:   13 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. DSM-IV-TR diagnosis of depression, defined as MDD, dysthymia, or substance-induced mood disorder meeting MDD or dysthymia symptom criteria
  2. DSM-IV-TR diagnosis of one or more non-nicotine SUD
  3. Some reported illicit drug use in the last 90 days
  4. 13-17 years of age
  5. parent or guardian willing to participate in study
  6. basic English competency (ability to converse in English)

Exclusion Criteria:

  1. Current and acute suicidal ideation at the level warranting inpatient treatment
  2. current psychotic symptoms
  3. the adolescent's sibling is already participating in the study
  4. if on psychiatric medications, a significant change in dosage levels in the prior 4 weeks -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00680966

Locations
United States, Oregon
Oregon Research Institute
Eugene, Oregon, United States, 97403
Sponsors and Collaborators
Oregon Research Institute
Investigators
Principal Investigator: Paul D Rohde, Ph. D. Oregon Research Institute
  More Information

No publications provided

Responsible Party: Oregon Research Institute
ClinicalTrials.gov Identifier: NCT00680966     History of Changes
Other Study ID Numbers: DA021357, 1RO1-DA021357
Study First Received: May 16, 2008
Last Updated: March 10, 2014
Health Authority: United States: Federal Government

Keywords provided by Oregon Research Institute:
Treatment efficacy
Family therapy
Teens
Substance abuse
Substance dependence

Additional relevant MeSH terms:
Depression
Depressive Disorder
Substance-Related Disorders
Behavioral Symptoms
Chemically-Induced Disorders
Mental Disorders
Mood Disorders

ClinicalTrials.gov processed this record on October 29, 2014